Agenus Inc. (NASDAQ:AGEN) Receives Average Recommendation of "Hold" from Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $9.00.

Several research analysts have recently issued reports on AGEN shares. B. Riley restated a "buy" rating on shares of Agenus in a report on Monday, April 21st. HC Wainwright restated a "neutral" rating on shares of Agenus in a report on Tuesday. StockNews.com upgraded shares of Agenus from a "sell" rating to a "hold" rating in a report on Friday, March 21st. Finally, Robert W. Baird lifted their price target on shares of Agenus from $3.00 to $4.00 and gave the company a "neutral" rating in a report on Tuesday.

Agenus Stock Performance

Shares of Agenus stock opened at $3.47 on Thursday. Agenus has a 52-week low of $1.38 and a 52-week high of $19.69. The stock has a market capitalization of $73.47 million, a price-to-earnings ratio of -0.31 and a beta of 1.48. The company's 50 day moving average price is $2.19 and its 200-day moving average price is $2.92.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to the consensus estimate of $26.38 million. As a group, equities research analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Large investors have recently added to or reduced their stakes in the stock. B. Riley Financial Inc. purchased a new position in Agenus during the fourth quarter valued at $2,074,000. Gilead Sciences Inc. purchased a new position in Agenus during the fourth quarter valued at $635,000. Invesco Ltd. purchased a new position in Agenus during the first quarter valued at $88,000. Jane Street Group LLC lifted its position in Agenus by 97.6% during the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company's stock valued at $290,000 after buying an additional 52,215 shares during the period. Finally, Deutsche Bank AG lifted its position in Agenus by 538.4% during the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company's stock valued at $168,000 after buying an additional 51,566 shares during the period. Institutional investors own 61.46% of the company's stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.